Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lidocaine
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aveva Gets FDA Nod for First Generic Lidocaine 1.8% Patch
Details : FDA has granted approval for its generic Lidocaine 1.8% Patch, a non-opioid topical treatment for post-herpetic neuralgia (PHN), providing patients suffering from localized nerve pain.
Product Name : ZTlido-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 26, 2025
Lead Product(s) : Lidocaine
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aveva Launches Generic Fentanyl TDS, Third Complex Transdermal Drug in 15 Months
Details : Fentanyl TDS, a prescriptional 3-day transdermal patch is launched for managing moderate to severe chronic pain which is generic equivalent to Duragesic.
Product Name : Duragesic-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 17, 2025
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable